As­ceneu­ron – 11/5/24

Asceneuron, a small Swiss biotech, has ter­mi­nat­ed a mid-stage test of a new type of oral drug (ASN51) for peo­ple with Alzheimer’s dis­ease citing strategic decisions, ac­cord­ing to the fed­er­al clin­i­cal tri­als data­base.

1 Discontinued Drug: ASN51 (small molecule), O-Glc­NAcase (OGA) inhibitor intended to curb the buildup of tau in pa­tients with Alzheimer’s